WILLIAM CONKLING
CIK 1852018 · Chief Commercial Officer · last filed 2026-06-11
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.45M
Companies
5
Total Filings
28
Lifetime Open-Market Net
$0
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IDT | Director | 673 | $67.88 | $45.7K | $0 | 1 | 2026-06-11 |
| TARA | Chief Commercial Officer | 69,992 | $3.94 | $275.8K | $0 | 3 | 2026-06-03 |
| Rafael Holdings, Inc. (RFL.WS) Delisted | Chief Executive Officer | 564,455 | $0.01 | $8.0K | $0 | 1 | 2025-04-24 |
| RFL | Chief Executive Officer | 537,001 | $2.10 | $1.13M | $0 | 15 | 2025-03-25 |
| Cyclo Therapeutics, Inc. (CYTHW) Delisted | Director | 77,884 | $0.03 | $2.5K | $0 | 8 | 2025-03-03 |
Recent Filings · Page 2 of 3
28 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-10-29 | RFL | Tax (F) | −3,431 | -$6.3K | EDGAR |
| 2024-09-24 | RFL | Tax (F) | −12,696 | -$21.9K | EDGAR |
| 2024-08-20 | Cyclo Therapeutics, Inc. (CYTHW) Delisted | Grant (A) | +8,731 | $0 | EDGAR |
| 2024-06-25 | RFL | Tax (F) | −13,295 | -$19.3K | EDGAR |
| 2024-06-05 | Cyclo Therapeutics, Inc. (CYTHW) Delisted | Grant (A) | +8,594 | $0 | EDGAR |
| 2024-03-25 | RFL | Tax (F) | +15,473 | $26.4K | EDGAR |
| 2024-02-15 | Cyclo Therapeutics, Inc. (CYTHW) Delisted | Grant (A) | +6,330 | $0 | EDGAR |
| 2023-12-26 | RFL | Tax (F) | +13,602 | $24.8K | EDGAR |
| 2023-11-30 | Cyclo Therapeutics, Inc. (CYTHW) Delisted | Grant (A) | +7,466 | $0 | EDGAR |
| 2023-10-26 | RFL | Grant (A) | +40,000 | $60.6K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.